Barrons : This Laser Maker Is on the Cutting Edge. Its Stock Is Cheap.

The Electric-Vehicle Future Is Nearly Here. This Overlooked Auto Components Giant Is Ready.
By Jack Hough

For all the hard-charging talk about electric cars, you might think that they were taking over the U.S. market. In fact, they’re expected to hit only about a 3.5% market share this year, up from 2.5% last year, according to researcher IHS Markit. So why do auto stocks seem to be rising in proportion to companies’ plug-in announcements?

Look to Europe for clues. Electric cars there are suddenly 14% of the market, or 23% if we count plug-in hybrids that burn fossil fuel for backup. Tax incentives help explain the uptake. France offers 7,000 euros (about $8,300) toward EVs, plus €5,000 for trading in clunkers. Germany has €9,000 subsidies, exemptions from yearly car taxes, local parking perks, and more.

In the U.S., meanwhile, a $7,500 credit for every electric vehicle phases out after companies sell 200,000 of them, so Tesla (ticker: TSLA) and General Motors (GM), the biggest EV players, no longer benefit. There is talk of lifting the cap, raising the dollar amount, and multiplying the number of charging stations as part of an infrastructure deal. Politicians will call that either a needed boost toward modernity or an unaffordable sop, depending on which you ask. But if it happens, the effect will be “a significant bullish catalyst for EV sales domestically over the coming years,” according to Wedbush Securities analyst Daniel Ives.

Tax perks aside, vehicle selection could also explain why the U.S. has been slow to go electric, but could catch up soon. Many Americans are light-truck drivers. They will have their choice of six electric trucks this year and 30 electric vehicles overall, up from zero trucks and 17 vehicles last year, according to Edmunds, the car reviewer.

“That acceleration that we see now, you will see it on the street three to five years from now, because then the cars are going to be ready for sale,” BorgWarner CEO Frédéric Lissalde told me about electric vehicles this past week.

Bear in mind that he is largely in the business of selling clutches and turbochargers to improve fuel efficiency in conventional cars and trucks. EVs don’t need clutches, which are used to change gears, because they don’t need multiple gears. And they don’t need turbochargers, which aid combustion in cylinders the way a bellows aids a fire, because electric vehicles have no cylinders, and no combustion.

BorgWarner (BWA) has prepared for this moment gradually over the past eight or so years by designing components like electric drive modules. Last year, it bought Delphi Technologies, which adds power electronics to make plug-in cars more efficient.

“Some people think that efficiency of the powertrain doesn’t apply to battery-electric because we don’t have fuel efficiency, so who cares, right?” Lissalde says. “That’s absolutely wrong. Efficiency in the battery-electric vehicle is as, or more, important than fuel efficiency [in conventional cars] because it touches the range or the cost of the vehicle with the size of the battery pack.”

Lissalde’s view of customer orders gives him as good an insight as anyone into long-term EV adoption. He says that by 2030, about one out of three cars produced will be battery-only, and another one out of three will be hybrid. By then, EVs will bring in 45% of BorgWarner’s revenue, he predicted at an investor presentation last month.

You would think that would cheer shareholders. General Motors stock is hitting new highs —new since emerging from bankruptcy in 2009, anyhow—seemingly on its doubling down on EVs. Ford Motor (F) stock is hitting levels not seen in years, for similar reasons.

Yet while BorgWarner shares have bounced back from last year’s market collapse, they’re still below where they were three years ago. It’s not business. Lissalde says demand is strong, and that the main growth constraint in the car industry now is the semiconductor shortage. Wall Street expects BorgWarner to generate nearly $1.1 billion in free cash next year, 10% of the company’s stock market value, and sees that figure rising by about 10% annually over the following three years.

Surely that kind of financial firepower will be useful for funding electric vehicle investments. Anyhow, what happened to the investor rotation into value stocks? BorgWarner is less than half as expensive as the S&P 500 index, relative to earnings.

Count Morgan Stanley analyst Adam Jonas among the bears. Management has done a good job of responding to a once-in-a-generation upheaval in the car business, he wrote after the investor day. Still, the gradual runoff of the company’s products for conventional fuel-burning cars is a sure thing, and the eventual profitability of its newer products for EVs remains to be seen. Plus, car makers could always make more components in-house.

But James Picariello at KeyBanc Capital Markets recommends buying Borg Warner shares. He predicts that the shift to electrification will increase the company’s dollar value of content per vehicle. Earnings estimates look beatable, and free cash flow is more than enough to pay for record research and development outlays, plus electric deal-making. In February, BorgWarner agreed to buy Akasol, a German maker of battery systems for commercial EVs, for $880 million.

Lissalde, who became chief executive in 2018, once managed BorgWarner’s turbo business, and says it still has some oomph left. “With any good hybrid propulsion architecture, it’s usually a turbocharged, downsized gasoline engine,” he says. “So for a lot of our combustion product lines, we still see growth for about the current decade. And then we’re just going to manage a product that is declining and another one that is growing.”

Jonas at Morgan Stanley, however, says that some car makers might shun hybrid architectures and go straight to battery-only vehicles. General Motors, for example, doesn’t make hybrids.

There are clear risks. But BorgWarner’s free cash flow is pegged at $5.7 billion cumulatively through 2025. For an $11 billion component maker, anything close to that figure will offer plenty of paths forward.

Barrons : This Laser Maker Is on the Cutting Edge. Its Stock Is Cheap.

This Laser Maker Is on the Cutting Edge. Its Stock Is Cheap.

For decades, the laser industry has been a fragmented collection of small players. There was, in fact, no laser-like focus. But a wave of mergers is changing the dynamic, creating long-term opportunities for investors.

For now, though, investors don’t know how to account for it all. Industry leader II-VI (ticker: IIVI) recently earned the winning bid for optical component maker Coherent (COHR). Rival offers from competitors Lumentum (LITE) and MKS Instruments (MKSI) forced II-VI to raise its offer several times and ultimately pay about $7 billion in cash and stock. II-VI’s stock dropped from a high of nearly $100 to the mid-$60s when the bidding war came to a close.

That was an overreaction, and II-VI stock has rebounded to about $76 in recent days. But there’s even more compelling value in the combination of II-VI and Coherent than the market is crediting. The stock should regain the $100 level and continue moving higher from there.

The tie-up is just the latest move in a wave of laser consolidation, following II-VI’s acquisition of Finisar in 2019 and Lumentum’s takeover of Oclaro in 2018. All of II-VI’s products are in photonics, or the science of light, for a wide range of applications. They include 3-D sensing technologies known as VCSEL and Lidar, which allow an Apple iPhone to recognize a user’s face and help a self-driving car avoid obstacles. The companies also supply key components used in data centers and fiberoptic telecom networks, as well as industrial cutting lasers, reminiscent of the weapon that supervillain Auric Goldfinger used on agent 007—“No, Mr. Bond, I expect you to die!” II-VI’s lasers are also used for actual weapon systems, including missile targeting.

Despite the recent turbulence for the stocks, industry consolidation is making the core players into more-diversified businesses better able to protect and develop their highly technical intellectual property. Increased scale also gives II-VI and Lumentum greater bargaining power with a concentrated group of customers. Apple (AAPL), Nokia (NOK), Cisco Systems (CSCO), Huawei, and Samsung Electronics (SSNLF) make up a critical mass of the industry’s customers.

Pennsylvania-based II-VI will fork over $220 in cash and 0.91 of its own shares for each Coherent share. The combination will nearly double the size of II-VI, which recently had a market value of about $8 billion. (As of now II-VI remains in the small-cap Russell 2000 index.) Its name, pronounced “two six,” refers to two groups in the periodic table used to make many of its laser products.

Adding Coherent will give II-VI greater exposure to end markets like life sciences, semiconductor capital equipment, and advanced laser-welding applications.

The deal is straight out of the company’s time-tested playbook. II-VI has completed some two-dozen mergers and acquisitions over the past 20 years, from small tuck-ins to the Finisar deal.

CEO Chuck Mattera, who holds a doctorate in chemistry, came to II-VI as a board member in 2000 after a 25 year career at Bell Laboratories and Alcatel-Lucent. Since then, II-VI has grown from about $150 million in annual revenue to an estimated $3 billion for this fiscal year, which ends in June.

“Acquisitions are a part of our strategy,” says Mattera, who took over the top job in 2016. “Putting together these two companies creates a global leader in photonics and complements our underlying capabilities. We believe that there’s just a tremendous and compelling opportunity that the combined companies will be uniquely positioned to pursue.”

II-VI and Coherent had combined sales of over $4 billion in 2020. The deal is scheduled to close by the end of this year, pending regulatory approval in the U.S. and China, which are home to the majority of II-VI’s employees and manufacturing facilities. Management expects the merger to eventually save $250 million a year in expenses—more than 6% of combined 2020 revenues—and to boost earnings per share in year two.

Most of II-VI’s and Coherent’s end markets are growing, as smartphones, cars, and trucks get more complex, fiber-intensive 5G networks are rolled out across the globe, and the digital world continues to migrate to the cloud. Wall Street analysts estimate 30% sales growth for stand-alone II-VI in pandemic-boosted fiscal 2021, followed by 10% growth next fiscal year. Coherent is seen growing revenues by about 15% in its fiscal 2021 and 2022, which end in September.

A more diversified portfolio should better insulate II-VI from the ups and downs of its customers. No single industry will represent more than 50% of the combined company’s sales, and investors may reward the shares with a higher valuation multiple as a result; II-VI stock trades for about 18 times estimated earnings over the coming year.

The average price target on II-VI stock is $106, or some 40% above current levels, with 75% of analysts rating the stock at Buy, according to FactSet.

The II-VI/Coherent deal also has a vote of confidence from private-equity firm Bain Capital, which took the unconventional step of purchasing at least $1.8 billion of equity in the combined company. Bain’s co-chairman, Steve Pagliuca, will also join II-VI’s board of directors.

Bain’s investment reduces II-VI’s required borrowing, with net debt of $4.9 billion anticipated at closing. That’s a manageable 3.8 times the combined company’s earnings before interest, taxes, depreciation, and amortization, or Ebitda. II-VI aims to get below three times within two years.

The market was too quick to dismiss the logic of a II-VI/Coherent tie-up. Investors now get a second swing at the shares.

>>> US Close Dow +0.89% S&P +0.77% Nasdaq +0.51% Russell +0.04%

Closing Stock Market Summary

The S&P 500 (+0.8%) and Dow Jones Industrial Average (+0.9%) set intraday and closing record highs on Friday, with the benchmark index topping the 4100 level for the first time. The Nasdaq Composite (+0.5%) overcome an early decline to close positive. The Russell 2000 (+0.04%) sneaked into the green amid a strong finish in the broader market.  

The session started with the market brushing off a hotter-than-expected Producer Price Index report for March, which showed producer prices for final demand increase 1.0% m/m (Briefing.com consensus +0.5%) and 4.2% yr/yr. Despite the potential for a spillover into consumer prices, the market trusted the Fed's thinking it'll be transitory. 

The difference makers today came out of the heavily-weighted S&P 500 information technology (+1.0%) and consumer discretionary (+1.2%) sectors, which boasted strong performances from Apple (AAPL 133.00, +2.64, +2.0%) and Amazon (AMZN 3372.20, +72.90, +2.2%) in a continuation of their monthly outperformances.

Buying activity increased noticeably into the close on no confirmed catalyst, with the health care (+1.2%), industrials (+1.0%), and financials (+0.9%) sectors rounding out the top spots. Conversely, the energy (-0.5%), consumer staples (-0.1%), and utilities (-0.1%) sectors closed slightly lower.  

The health care sector advanced without the leadership of Johnson & Johnson (JNJ 161.25, -1.72, -1.0%), which lost ground amid concerns surrounding the rollout and safety of its COVID-19 vaccine. Within the industrials sector, Boeing (BA 252.36, -2.59, -1.0%) advised customers to address a potential electrical issue in a specific group of 737 MAX planes prior to further operations.

Separately, the latest Flow Show report from BofA Securities indicated that total global equity inflows over the past five months ($576 billion) has exceeded total inflows for the past 12 years ($425 billion). Some attributed this eye-popping statistic to the muted price action during most of the day, but there still appeared to be an underlying hunger for risk assets.  

In the Treasury market, the 10-yr yield settled three basis points higher at 1.67%, or slightly lower than where it was trading immediately before, and after, the PPI data. The 2-yr yield increased one basis point to 0.15%. The U.S. Dollar Index increased 0.1% to 92.17. WTI crude futures decreased 0.5%, or $0.32, to $59.29/bbl.

Reviewing Friday's economic data:

  • The Producer Price Index for final demand increased 1.0% month-over-month in March  consensus +0.5%). The index for final demand, excluding food and energy, jumped 0.7% m/m (Briefing.com consensus +0.2%. On a year-over-year basis, the index for final demand was up 4.2% (highest since 12 months ending September 2011), versus 2.8% in February. The index for final demand, excluding food and energy, was up 3.1% yr/yr, versus 2.5% in February.
    • The key takeaway from the report isn't in the headline numbers. They are important, but the key takeaway is the pipeline pressures evident in the index for processed goods for intermediate demand, which increased 4.0% m/m in March (largest jump since August 1974), and in the index for unprocessed goods for intermediate demand, which surged 9.3% m/m (highest since November 2006). Those large increases point to inflation issues that are apt to linger for producers and which could potentially spill over into consumer prices.
  • Wholesale inventories increased 0.6% m/m in February (consensus 0.5%) following an upwardly revised 1.4% increase (from +1.3%) in January.

Looking ahead, investors will receive the March Treasury Budget on Monday. 

  • Russell 2000 +13.6% YTD
  • Dow Jones Industrial Average +10.4% YTD
  • S&P 500 +9.9% YTD
  • Nasdaq Composite +7.9% YTD

>>> US Gapping down

Gapping down
In reaction to earnings/guidance
:

  • JKS -10.9%, WDFC -7.3%, PSMT -3%, IMOS -0.6% (Q1 revs), TSM -0.5% (March Sales)

Other news:

  • PRVB -37.9% (FDA identifies deficiencies in BLA application for teplizumab)
  • ITRM -15.5% (discloses FDA notice that it needs more time to review materials that have been provided by the company)
  • GSL -5.4% (stock offering)
  • DLPN -4.7% (says some prior financials should no longer be relied upon due to accounting error)
  • SNDX -4.6% (FDA grants Orphan Drug Designation to axatilimab)
  • RMBL -4.4% (prices offering of 1,048,998 shares of its Class B Common Stock at $38.00 per share)
  • KMPH -2.4% (amends licensing agreement with Gurnet Point Capital following FDA approval of AZSTARYS)
  • UCTT -1.5% (prices offering of 3,181,818 shares of its common stock at $55.00 per share)
  • ORTX -1% (ADS offering)

Analyst comments:

  • CS -2.5% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
  • BTI -2.4% (downgraded to Neutral from Overweight at JP Morgan)
  • ATUS -1.6% (downgraded to Neutral from Buy at Citigroup)
  • BCC -1.2% (downgraded to Neutral from Buy at DA Davidson)
  • CHUY -1.1% (downgraded to Hold from Buy at Stifel)
  • GD -0.8% (downgraded to Underperform from Outperform at Wolfe Research)

>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:

  • LEVI +5.5% (also increases dividend), AFYA +2.2% (also announces acquisition of Medical Harbour), SMG +1.4% (raises FY21 rev guidance above consensus; raises EPS guidance above consensus at the mid-point)

Other news:

  • CELC +52.7% (PFE announces licensing agreement with CELC for gedatolisib)
  • GLSI +29% (reports Phase IIb data supporting GP2 clinical outcome of 0% metastatic breast cancer recurrences over 5 years)
  • AFMD +27.5% (presents Phase 1 study of cord blood-derived natural killer cells pre-complexed with innate cell engager AFM13 at AACR)
  • LHDX +14.6% (confirmed it can successfully identify the "double mutant" variant of COVID-19 with its Lucira molecular test kit)
  • TXMD +9.1% (announces approvals for BIJUVE in the UK and Belgium)
  • FUBO +8.4% (acquires streaming rights to the Qatar World Cup 2022)
  • SOGO +6% (reports circulate that China's antitrust regulators are poised to clear Tencent's (TCEHY) buyout of SOGO)
  • TRQ +4.2% (Turquiose Hill Resources and Rio Tinto (RIO) signs agreement for funding Oyu Tolgoi)
  • RDHL +4% (reports Phase 2/3 COVID-19 study of Opaganib passes fourth DSMB review)
  • SUNW +3.4% (to acquire Solcius)
  • HGEN +3.1% (announces positive results from the Phase 1 safety and bioimaging trial of its second Humaneered antibody, ifabotuzumab, in patients with glioblastoma multiforme)
  • IOVA +2.8% (announced data from Cohort 2 in the C-144-01 study of lifileucel in advanced melanoma)
  • GSX +2.8% (firmly denies the false and ungrounded allegations raised in a report by Grizzly Research; believes report contains numerous errors, unsubstantiated statements, and misinterpretation of information)
  • UPST +2.6% (prices follow-on offering of 2 mln shares of common stock at $120.00 per share)
  • NBIX +2.5% (to present data from its Neurology portfolio)
  • BKD +2% (reports March occupancy metrics)
  • CCK +2% (to sell its European Tinplate business to KPS Capital for €1.9 bln; also to sell its EMEA food and consumer packaging business to KPS Capital for €2.25 bln)
  • JCI +1.5% (acquires Silent-Aire; to be immediately accretive to FY22 earnings)

Analyst comments:

  • DAN +2.7% (upgraded to Overweight from Equal Weight at Barclays)
  • CCL +2.1% (upgraded to Outperform from Neutral at Credit Suisse)
  • COMM +2.1% (upgraded to Buy from Neutral at Rosenblatt)
  • OKTA +2.1% (upgraded to Buy from Neutral at BTIG Research)
  • HON +2% (upgraded to Buy from Hold at Deutsche Bank)
  • PM +1.3% (upgraded to Overweight from Neutral at JP Morgan)
  • IBA +1.1% (upgraded to Overweight from Neutral at JP Morgan)